News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
94,352 Results
Type
Article (6773)
Company Profile (39)
Press Release (87540)
Multimedia
Podcasts (6)
Webinars (1)
Section
Business (27766)
Career Advice (127)
Deals (4266)
Drug Delivery (32)
Drug Development (14131)
Employer Resources (12)
FDA (2869)
Job Trends (2129)
News (49573)
Policy (6031)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (428)
Accelerated approval (3)
Adcomms (7)
Allergies (32)
Alliances (9028)
ALS (13)
Alzheimer's disease (265)
Antibody-drug conjugate (ADC) (45)
Approvals (2866)
Artificial intelligence (46)
Autoimmune disease (9)
Automation (3)
Bankruptcy (19)
Best Places to Work (1813)
BIOSECURE Act (16)
Biosimilars (77)
Biotechnology (26)
Bladder cancer (22)
Brain cancer (6)
Breast cancer (53)
Cancer (467)
Cardiovascular disease (22)
Career advice (111)
Career pathing (3)
CAR-T (21)
Cell therapy (85)
Cervical cancer (3)
Clinical research (11539)
Collaboration (194)
Compensation (43)
Complete response letters (9)
COVID-19 (545)
CRISPR (5)
C-suite (52)
Cystic fibrosis (13)
Data (441)
Denatured (2)
Depression (6)
Diabetes (36)
Diagnostics (586)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (26)
Drug pricing (24)
Drug shortages (1)
Duchenne muscular dystrophy (26)
Earnings (9516)
Editorial (6)
Employer branding (3)
Employer resources (10)
Events (12298)
Executive appointments (124)
FDA (3216)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (156)
Gene editing (24)
Generative AI (6)
Gene therapy (85)
GLP-1 (109)
Government (1325)
Grass and pollen (1)
Guidances (12)
Healthcare (1987)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (43)
Indications (9)
Infectious disease (581)
Inflammatory bowel disease (47)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (12)
Interviews (11)
IPO (2123)
IRA (13)
Job creations (385)
Job search strategy (107)
Kidney cancer (2)
Labor market (2)
Layoffs (55)
Leadership (1)
Legal (559)
Liver cancer (13)
Lung cancer (76)
Lymphoma (29)
Machine learning (1)
Management (2)
Manufacturing (114)
MASH (12)
Medical device (1207)
Medtech (1208)
Mergers & acquisitions (2256)
Metabolic disorders (87)
Multiple sclerosis (18)
NASH (2)
Neurodegenerative disease (18)
Neuropsychiatric disorders (1)
Neuroscience (341)
NextGen: Class of 2025 (700)
Non-profit (349)
Northern California (488)
Now hiring (11)
Obesity (32)
Opinion (48)
Ovarian cancer (20)
Pain (9)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (31)
Patient recruitment (19)
Peanut (21)
People (7999)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3794)
Phase II (4799)
Phase III (4237)
Pipeline (303)
Policy (51)
Postmarket research (297)
Preclinical (1480)
Press Release (66)
Prostate cancer (19)
Psychedelics (5)
Radiopharmaceuticals (38)
Rare diseases (73)
Real estate (918)
Recruiting (4)
Regulatory (4798)
Reports (11)
Research institute (387)
Resumes & cover letters (11)
RNA editing (1)
RSV (11)
Schizophrenia (11)
Series A (36)
Series B (15)
Service/supplier (3)
Sickle cell disease (7)
Southern California (501)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (574)
State (1)
Stomach cancer (3)
Supply chain (11)
Tariffs (10)
The Weekly (4)
United States (4280)
Vaccines (189)
Venture capitalists (6)
Weight loss (16)
Women's health (3)
Date
Today (33)
Last 7 days (104)
Last 30 days (527)
Last 365 days (6382)
2025 (1976)
2024 (6641)
2023 (7092)
2022 (9215)
2021 (9768)
2020 (8446)
2019 (5942)
2018 (4540)
2017 (5111)
2016 (4653)
2015 (5295)
2014 (3733)
2013 (2895)
2012 (2984)
2011 (3146)
2010 (2572)
Location
Africa (92)
Alabama (11)
Alaska (1)
Arizona (12)
Arkansas (2)
Asia (7625)
Australia (906)
California (1175)
Canada (241)
China (175)
Colorado (35)
Connecticut (27)
Delaware (41)
Europe (13958)
Florida (146)
Georgia (20)
Idaho (13)
Illinois (51)
India (12)
Indiana (40)
Iowa (1)
Japan (30)
Kansas (7)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (322)
Massachusetts (815)
Michigan (24)
Minnesota (45)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (463)
New Mexico (4)
New York (337)
North Carolina (204)
North Dakota (7)
Northern California (488)
Ohio (40)
Oklahoma (7)
Oregon (3)
Pennsylvania (195)
Puerto Rico (1)
Rhode Island (5)
South America (135)
South Carolina (2)
Southern California (501)
Tennessee (4)
Texas (159)
Utah (24)
Virginia (18)
Washington D.C. (7)
Washington State (95)
Wisconsin (8)
94,352 Results for "hcw biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
March 28, 2025
·
14 min read
Press Releases
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024
·
4 min read
Business
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its first quarter ended March 31, 2024.
May 15, 2024
·
13 min read
Business
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
April 1, 2024
·
14 min read
Press Releases
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
February 3, 2025
·
7 min read
Press Releases
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
November 18, 2024
·
6 min read
Press Releases
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
November 15, 2024
·
12 min read
Press Releases
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
January 15, 2025
·
6 min read
Drug Development
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
HCW Biologics Inc.announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy.
November 8, 2023
·
8 min read
Press Releases
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
August 15, 2024
·
12 min read
1 of 9,436
Next
